Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IBRC .0029: 1st Nations, Federal Law and CBIS(!):
"iBrands Corporation Inc. (OTC PINK: IBRC) is pleased to announce that it has signed an "Exclusive Supply Contract" with Free Spirit Organics LLC., an Indian Tribal Company made up of the Winnemucca, Northern Shoshoni and Washoe Indian Tribes. They market their products under the name CBDoil. The term of the contract is for 1 year and is renewable.
Chief Bill Bills stated, "This is a very exciting time for our Tribes right now. The demand for our products is growing at 400% per month and we have been having a hard time securing the raw oil and having to go to several places to fill orders. Now with the new regulations classifying cannabinoids as a class 1, we think our sales will grow even faster because of our ability to fill orders other companies can't. The laws are still up in the air, but because of our sovereign status we can send products across state lines from tribe-to-tribe much easier than most. Many of the Indian Casinos are carrying our products in their commissaries. We also have 3,000 Tribal stores that are starting to carry CBDoil as well."
The first order is for 1,000 kilograms (2,200 pounds) and will be delivered by the end of February. Ongoing demand is expected to be between 200-250 kilograms per month. In the past, the Tribe has been paying $25,000 on up to $48,000 per kilogram.
"Our connections within the industry have helped us secure volume pricing. In comparison, the first contract was filled at $13,000 per kilo," said Michael Ogburn, CEO of iBrands.
Ogburn also went on, "We are really focusing on growing our Purest CBD right now. The cannabinoid market is the future in our opinion and we are putting a lot of effort into it. The agreement is exclusive and was signed February 6, 2017."
Got a Colonoscopy and Endoscopy in an hour and a half, hold down the forts!!!
$SNAP IPO is probably the most overrated anticipated IPO. I don't have a Snapchat because I think it's retarded but we'll see what it does. Will $FB do to Snapchat with FB stories, what it did to Periscope with FB live?
Damn Mean nice DD gonna have to do some major DD on this one over the weekend
$APHD short squeeze "S-1 RW" on friday after hours - .0029 > 51 million outstanding shares and only $14k notes as of Q3 2013.
see s-1 from December, 5000% increase in short volume in January and likely continued into February. after hours RW says no shares were issued and no shares will be issued as effectively canceled the purchase agreement.
https://www.stockscores.com/quickreport.asp?ticker=aphd&x=0&y=0
10k due expecting significant revenue reported > gained some major contracts last fall with "robin jeans" "toms shoes" and "major league sports association"
release says quote "is pleased to announce to its shareholders the completion and delivery of product sale of $250,000+ anti-counterfeit device units for the associations licensed apparel vendors."
key word UNITS for VENDERS: mlb, nba, nfl, etc etc etc.
counterfeits represent over 10% of the global apparel mkt
APHD gives 30 DAY FREE PROOF OF CONCEPT TRIAL for french luxury goods company with over $500mil revenue> brand protection is a big deal for luxury designers like louis vuitton , chanel, gucci etc etc where the real deal cost $500-1000 but china counterfiters flooding online mkt place with knock offs for less than $100 - this is a signifcant loss for luxury designers and explains why the "online brand protection market" is expected to reach $200 billion by 2020.
to see the us major league sports association as APHD client is significant as they represent $13 billion in sports licensing apparel sales per year
http://www.otcmarkets.com/stock/APHD/news/Appiphany-Technologies-Announces-Completion-and-Delivery-of-Anti-Counterfeit-Device-Labels-to-Major-League-Sports-Association?id=139430&b=y
http://www.otcmarkets.com/stock/APHD/news/Appiphany-Technologies-Announces-French-Luxury-Goods-Designer-the-Latest-Watchdog-Proof-of-Concept-Client?id=137799&b=y
http://www.otcmarkets.com/stock/APHD/news/Appiphany-Technologies-Announces-Robin-s-Jean--California--The-Latest-Watchdog-Client?id=137099&b=y
POT STOCKS TAKING A DIVE TODAY FEDS WANT TO IMPLEMENT NEW LEGISLATION TO REGULATE THEM MIGHT BE A GOOD TIME TO SELL AND WAIT TO SEE WHAT HAPPEN WHEN THE DUST SETTLES.
Move back we can start a real Boilerroom
Nothing like Southern Cali
Yeah that's where I use to be at
That's too far I live in Souther California
Also got footage of him from a camera from one of the places he entered like a big lumbering Baffoon.
He's up in Santa Cruz I actually found his neighborhood it's a trailer park, haven't found his house yet though
Lol yea man I would if I could
Lol maybe you can find the dumbo that decided to buy an industrial mower and knock some sense into him for me
I live in California... lol
APPARENTLY SOME ASSH0L* IN CALIFORNIA STOLE MY IDENTITY AND RACKED UP A BUNCH OF CHARGES THE LAST TWO DAYS BUYING LAWN MOWER EQUIPMENT AND A BUNCH OF OTHER RANDOM ASS B/S I GOT YOU B!!! YOU THINK YOU CAN STEAL THE IDENTITY OF MULTIPLE PEOPLE AND GET AWAY WITH IT I GOT CONNECTIONS COMPADRE YOURE TOAST!!!
THIS HAS BEEN A PUBLIC SERVICE ANNOUNCEMENT FROM STOCKWHALE ALWAYS BE VIGILANT ABOUT WHO YOU GIVE YOUR PERSONAL AND CREDIT CARD INFO TO AND ALSO WHERE YOU SWIPE IT!!!
Thank you my friend I will check it out
the next EWLL and heres why
EMSF-CEO:Steve-Rubakh 26.9M Shares + 3M Warrants,exercisable @ 0.74==>
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128841736
EMSF as of Feb 8, 2016, Float-15M 42M shares outstanding, 27M owned by CEO
CEO bought 2.7M @ .03 on June 2016 for $81,000. He owns a massive number of shares. Float is tiny. Big moves coming!
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11598019
EMSF Merger news pending. Name change to Merger2O (M2O). Looks like they formed a portfolio umbrella company and joined with another transportation company 888.Rideshare.
"Effective 02/06/2017, Merger2O (formerly Ems Find, Inc), (OTCQB: EMSF) officially commenced operations as a publicly traded portfolio company" ...
"Each merger partner will remain the majority owner of its own unique an anti-dilutable preferred share class with intention to execute IPO within 24 months which will position current shareholders to receive a stock dividend."
<---Explains the raise in a/s to accommodate those newly registered preferred shares.
$ORRV news just out
Oceanic Research & Recovery (ORRV) Intends to File With OTC Markets to Remove Stop Sign
Feb 19, 2017
OTC Disclosure & News Service
Colleyville, TX -
Oceanic Research & Recovery, Inc. (PINKSHEETS: ORRV) announced today that it intends to file certain limited information with OTC Markets consistent with the OTC Pink® Basic Disclosure Guidelines.
Willard McCusker, Oceanic Research & Recovery's President & CEO, said, "We are pleased to announce this first step in increasing the disclosure and transparency of the operations and performance of Oceanic Research & Recovery as well as all the McCusker Holding Corp subsidiaries to our public shareholders, our immediate goal is to get the stop sign removed. We plan to take additional steps in the future, consistent with our goal of building ORRV into a listed company over the next 2-3 years."
Oceanic Research & Recovery aka McCusker Holding Corp. is now a leading national provider of consumer electronic tablet devices, smart watches, screen protection devices and other consumer electronic warranty products. McCusker also provides help desk and warranty insurance administration serves for a wide variety of industries. It also has created specialized service programs for the consumer electronics and the heating, ventilating, and air conditioning (HVAC) industries. The Company services 43 countries. McCusker's clients include : OEM's, retailers, law firms, underwriters, and third party administrators. The Company is a true leader of developing innovative solutions for help desk and warranty insurance administration support services.
Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although McCusker Holding Corp. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, McCusker Holding Corp. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company's ability meet the conditions necessary to complete the proposed APO transaction.
Copyright © 2017 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Heck yes it did!!! Was up $45,000 by time took profits locked in $30,000
Haha that's what's up broski that $TOPS did us well!!!
Came up $40,000 last week. Very happy camper!!! Weeeeeeeeeeeee!!!!
Bro lemme get a weeeeeee!!!! Haha
Yes told you load up my friend... Weeeeeeeeeeee!!!!$$$$
Lol bruh. Where you at man, $GLS went bonkers after you called it.
$TOPS good shipping company to invest long term in. Going to be a great year for them.
$PMCB PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA PMCB
https://globenewswire.com/news-release/2017/01/30/911996/0/en/PharmaCyte-Biotech-Retains-Facet-Life-Sciences-to-Guide-Pancreatic-Cancer-Therapy-Development-Lifecycle-with-FDA.html
Go $PMCB
lol do you remember my music video page?
lol what is it it's not showing
No probs!!!
BSTG also running on news AH, might fill that gap
I'm on it.
Thanks
Never too late to get into $TOPS
Nice call on TOPS,DRYS soon maybe? or SINO again as well as I love SINO.
Keep an eye on the people who are happy for your achievements, these are the people you want to keep around.
ADVT 'NEW Products NewMJ to watch closely
just posted on ADvantis website:
http://advantiscorp.com/advantis-holdings-products/
AMSTER-CAN PREMIUM VAPES
100% organic from seed to Cartridge
We created a process which makes it easy to add new flavors (strains) without substituting quality. Initial launch 4 Strains.
Machinery to Mass Produce to keep costs down
Best quality domestic cartridges and materials… Won’t leak or have electronic failures.
Consumer can scan QR code to see lab tested results.
Highest THC CBD Levels on the market ( cannabinoids )
THE HEMPEROR’S CLUB PREMIUM VAPES
The Hemperor’s Club is Southern California’s leading exotic flower and vape pen producers.
Advantis has already begun full-scale production for Hemperor’s Club, who is a member/provider for several Southern California dispensaries. “This is an excellent opportunity to spread the name and idea of Amstercan to become a more recognized brand name in the industry,” Advantis CEO, Christopher Swartz, said. “Hemperor’s Club has done a great job of doing this themselves, so this is a mutually beneficial relationship. Hemperor’s club will elevate the image of their most premium brands, and that will lead to another consistent revenue stream for Amstercans.” Hemperor’s Club services thousands of Southern California member/patients with the supply of their most exotic strains of cannabis and vape pens.
launching new CBD's line:
and if that's not enough.. a celebrity will soon represent the company..and that not UFC legend Kimo Leopoldo with his favorite Amstercan. Black Label OG Cush.
:)
happy trading
OTC Disclosure & News Service
http://www.otcmarkets.com/stock/ADVT/news
Authorized Shares 1,000,000,000 a/o Jan 01, 2016
Outstanding Shares 918,969,715 a/o Aug 23, 2016
Title
OTC Disclosure & News Service
-
Advantis Corp. Taking Steps to Become SEC Fully-Reporting Company
NEWPORT BEACH, CA--(Marketwired - Feb 9, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is taking steps to become a fully-reporting public company. The rate at which Advantis has been growing revenue and acquiring new shareholders is cited as the reason for the decision. An SEC fully-reporting company is one that must adhere to more stringent SEC reporting guidelines that are designed to increase transparency for investors.
Jan 30, 2017 Advantis Corp. Packages Hemperor's Club Premium Cannabis Press Release
Jan 23, 2017 Advantis Corp. Developing Rosin Press for Home Use Press Release
Jan 17, 2017 Advantis Corp. Boosts Bottom Line, Reduces Debt Press Release
Jan 10, 2017 Advantis Corp. Rolls Out New Products Press Release
Jan 3, 2017 Advantis Corp. Acquires Large Commercial Space Press Release
Dec 19, 2016 Advantis Corp. Reviews Progress, Forecasts Revenue Explosion for 2017 Press Release
Dec 5, 2016 Advantis Corp. Acquires Rights to Nugsmasher Line of Rosin Presses Press Release
Nov 30, 2016 Advantis Corp. Amstercan Sales Increase Three-Fold Press Release
Nov 21, 2016 Advantis Corp. Surging Sales Lead to Premium Product Development Press Release
Nov 17, 2016 Advantis Corp. Launches Rosin6 Marketing Campaign, Announces First Sales Press Release
Nov 14, 2016 Advantis Corp. Forges New Trail In Cannabis Extraction, Developing New Product Lines Press Release
Nov 10, 2016 Advantis Corp. Lauds Passage of California's Prop 64 Press Release
Nov 7, 2016 Advantis Corp. Signs Distribution Agreement with California's Largest Medical Marijuana Delivery Service Press Release
Nov 4, 2016 Advantis Corp. Launches New Revolutionary Rosin6 Rosin Press Press Release
Nov 1, 2016 Prop 64 Voting Fuels Cannabis Sector -- Advantis Corp. to Expand on Distribution Deals Across the Country and in Final Stages on Agreement with one of California's Largest Delivery Services Press Release
Sep 20, 2016 Advantis Corp. Licenses Amstercan Packaging Process, Brands OG Kush, Blue Dream, and Gorilla Glue Press Release
Sep 14, 2016 Advantis Corp. Receives Revolutionary Patented Packaging Equipment for Preserving Cannabis Press Release
Aug 30, 2016 Advantis CEO, Christopher Swartz, Addresses Recent Unauthorized Promotion of Advantis Stock by Stellar Media Group and Others. Press Release
Aug 29, 2016 Advantis CEO, Christopher Swartz, Addresses Recent Unauthorized Promotion of Advantis Stock by Stellar Media Group and Others. Press Release
Jun 27, 2016 Advantis Corp. Announces Critical Talks With Leafhead.com and Hires Chief Compliance Officer of Operations Press Release
Jun 22, 2016 Advantis Corp. Signs Licensing Agreement With N2 Packaging Systems Press Release
Jun 13, 2016 Advantis CEO, Christopher Swartz, is Featured in an Exclusive New Interview at SmallCapVoice.com Press Release
Jun 7, 2016 Advantis Corp. Announces Relationship With Major Hemp/CBD Manufacturer Out of Colorado Press Release
May 3, 2016 Advantis Corp. Appoints Chief Medical Director to Develop CBD Based Nutraceuticals Press Release
Mar 28, 2016 New Advantis Corp. CEO Shares Vision, Identifies Future Revenue Press Release
Mar 21, 2016 Advantis Corp. Delivers Products and Services to California Medical Marijuana Business Press Release
Mar 15, 2016 Advantis Adds Firepower to Executive Team Press Release
Feb 22, 2016 Advantis Corp. Delivers LipMedRX to Southern California Retailer Press Release
Feb 10, 2016 Advantis Corp. Establishes Advantis Cannabis, LLC in Washington Press Release
Feb 1, 2016 Advantis Corp. Signs Contract With Regulatory and Environmental Consultant, EARSI Press Release
Jan 27, 2016 Advantis Corp. Steps Toward Oregon Cannabis Market Press Release
Jan 19, 2016 Advantis Corp. Searches for West Coast Distribution Hub Press Release
Jan 11, 2016 Advantis Corp. Recaps 2015, Moves Corporate Office Press Release
AmsterCan's sold on https://www.speedweed.com/product-category/flowers/
NugSmasher Line on Amazon.com: https://www.amazon.com/s/ref=nb_sb_noss_2?url=search-alias%3Daps&field-keywords=nugsmasher
$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers PMCB
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.12 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.
Abdominal Cancers
According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:
Colorectal: 132,000
Liver: 62,000
Pancreatic: 49,000
Ovarian: 22,000
To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.
PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.
PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.
Breast Cancer
PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.
In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.
Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.
The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
$LVGI Limitless Venture Group Inc. (OTCBB: LVGI)
Bruh it's still mad early to get back in $BMXC trust me we hitting Pluto in this one weeeeee!
BMXC beast . shoulda stuck with that one ... check out my ITKH sticky bro. folks gonna be all over it soon. cdel buying up bottom
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1056
|
Created
|
10/12/16
|
Type
|
Free
|
Moderators tripil7z Grolden ©PROPHETABLE Mean Weimaraner RedSox04 |
Posts Today
|
0
|
Posts (Total)
|
1056
|
Posters
|
|
Moderators
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |